Krysan K - Search Results

1

Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer.

Mao JT, Cui X, Reckamp K, Liu M, Krysan K, Dalwadi H, Sharma S, Hazra S, Strieter R, Gardner B, Dubinett SM. Mao JT, et al. Among authors: krysan k. Clin Lung Cancer. 2005 Jul;7(1):30-9. doi: 10.3816/CLC.2005.n.019. Clin Lung Cancer. 2005. PMID: 16098242 Review.

2

Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion.

Dohadwala M, Batra RK, Luo J, Lin Y, Krysan K, Pold M, Sharma S, Dubinett SM. Dohadwala M, et al. Among authors: krysan k. J Biol Chem. 2002 Dec 27;277(52):50828-33. doi: 10.1074/jbc.M210707200. Epub 2002 Oct 21. J Biol Chem. 2002. PMID: 12393872 Free PMC article.

3

Abnormal interleukin 10Ralpha expression contributes to the maintenance of elevated cyclooxygenase-2 in non-small cell lung cancer cells.

Heuze-Vourc'h N, Zhu L, Krysan K, Batra RK, Sharma S, Dubinett SM. Heuze-Vourc'h N, et al. Among authors: krysan k. Cancer Res. 2003 Feb 15;63(4):766-70. Cancer Res. 2003. PMID: 12591723

4

COX-2-dependent stabilization of survivin in non-small cell lung cancer.

Krysan K, Merchant FH, Zhu L, Dohadwala M, Luo J, Lin Y, Heuze-Vourc'h N, Põld M, Seligson D, Chia D, Goodglick L, Wang H, Strieter R, Sharma S, Dubinett S. Krysan K, et al. FASEB J. 2004 Jan;18(1):206-8. doi: 10.1096/fj.03-0369fje. Epub 2003 Nov 3. FASEB J. 2004. PMID: 14597555

5

Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer.

Põld M, Zhu LX, Sharma S, Burdick MD, Lin Y, Lee PP, Põld A, Luo J, Krysan K, Dohadwala M, Mao JT, Batra RK, Strieter RM, Dubinett SM. Põld M, et al. Among authors: krysan k. Cancer Res. 2004 Mar 1;64(5):1853-60. doi: 10.1158/0008-5472.can-03-3262. Cancer Res. 2004. PMID: 14996749

6

Cyclooxygenase-2-dependent expression of survivin in non-small cell lung cancer.

Krysan K, Dohadwala M, Luo J, Lin Y, Zhu L, Heuze-Vourc'h N, Goodglick L, Merchant F, Seligson D, Pold M, Strieter R, Sharma S, Dubinett S. Krysan K, et al. Chest. 2004 May;125(5 Suppl):140S. doi: 10.1378/chest.125.5_suppl.140s. Chest. 2004. PMID: 15136466 No abstract available.

7

Multifaceted roles of cyclooxygenase-2 in lung cancer.

Riedl K, Krysan K, Põld M, Dalwadi H, Heuze-Vourc'h N, Dohadwala M, Liu M, Cui X, Figlin R, Mao JT, Strieter R, Sharma S, Dubinett SM. Riedl K, et al. Among authors: krysan k. Drug Resist Updat. 2004 Jun;7(3):169-84. doi: 10.1016/j.drup.2004.04.003. Drug Resist Updat. 2004. PMID: 15296859 Review.

8

Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer.

Krysan K, Dalwadi H, Sharma S, Põld M, Dubinett S. Krysan K, et al. Cancer Res. 2004 Sep 15;64(18):6359-62. doi: 10.1158/0008-5472.CAN-04-1681. Cancer Res. 2004. PMID: 15374938

9

Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancer.

Põld M, Krysan K, Põld A, Dohadwala M, Heuze-Vourc'h N, Mao JT, Riedl KL, Sharma S, Dubinett SM. Põld M, et al. Among authors: krysan k. Cancer Res. 2004 Sep 15;64(18):6549-55. doi: 10.1158/0008-5472.CAN-04-1225. Cancer Res. 2004. PMID: 15374967

10

Prostaglandin E2-dependent enhancement of tissue inhibitors of metalloproteinases-1 production limits dendritic cell migration through extracellular matrix.

Baratelli FE, Heuzé-Vourc'h N, Krysan K, Dohadwala M, Riedl K, Sharma S, Dubinett SM. Baratelli FE, et al. Among authors: krysan k. J Immunol. 2004 Nov 1;173(9):5458-66. doi: 10.4049/jimmunol.173.9.5458. J Immunol. 2004. PMID: 15494493

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

62 results

Search Page

Filters